--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...

REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...

REYKJAVIK, ICELAND (July 20, 2022) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...

The GPR133 receptor is expressed by osteoblasts, the cells that make bone. The study suggests that this receptor helps those cells sense two kinds of input: mechanical strain and signals relayed by ...

Osteoporosis is a degenerative, debilitating bone disease that is increasingly prevalent in postmenopausal women. Despite its being classified as one of the four most dangerous health issues today, a ...

According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis. Patients with advanced ...

A research team from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine of the University of Hong Kong ...